MUMBAI, India, Nov. 2 -- Intellectual Property India has published a patent application (202617096781 A) filed by Beijing Chest Hospital, Capital Medical University; and Beijing Tuberculosis And Thoracic Tumor Research on August 11, 2026, for Anti-Mycobacterial Infection Pharmaceutical Composition.
Inventors include Xu, Jian; Lu, Yu; Pan, Junhua; Zhang, Ye; Cheng, Kai; and Liang, Wenwen.
The application for the patent was published on October 30, 2026, under issue no. 44/2026.
Abstract: The present invention belongs to the technical field of biopharmaceuticals and specifically relates to use of a pharmaceutical composition in combating mycobacterial infection. The use of zuclopenthixol in combination with bedaquiline exhibits significantly enhanced anti-mycobacterial infection activity. Compared to the use of bedaquiline alone, the use of 2 µg/ml zuclopenthixol in combination with bedaquiline results in varying reductions in colony counts of the MmpL5-MmpS5 strain when the concentration of bedaquiline ranges from 1/16 MIC to 2 MIC. As an enhancer of bedaquiline, zuclopenthixol can enhance the anti-mycobacterial infection activity of bedaquiline. The minimum inhibitory concentration of zuclopenthixol against the Rv0678 mutant strain in vitro is 16 µg/ml, and the minimum inhibitory concentration of BDQ against the Rv0678 mutant strain in vitro is 1 µg/mL. The use of 1 µg/ml zuclopenthixol in combination with BDQ reduces the MIC of BDQ against the Rv0678 mutant strain from 1 µg/ml to 0.03 µg/ml (a 32-fold increase in efficacy), which is lower than the MIC against the wild strain H37Rv (0.06 µg/ml), reversing resistance to BDQ and further enhancing the anti-mycobacterial infection activity.
Disclaimer: Curated by HT Syndication.
